[Protective effect of mitochondria-targeted antioxidant peptide SS-31 in sepsis-induced acute kidney injury]

Min Sun1, Jianwei Ma, Jihui Ye

  • 1Department of Intensive Care Unit, Ningbo First Hospital, Ningbo 315010, Zhejiang, China. Corresponding author: Zhu Jianhua,

Abstract

Insights

Mitochondria-targeted antioxidant peptide SS-31 protects against sepsis-induced acute kidney injury (AKI) by maintaining mitochondrial function and reducing cell apoptosis. This study highlights SS-31 as a potential therapeutic agent for AKI.

Area of Science:

  • Nephrology
  • Mitochondrial Medicine
  • Sepsis Research

Background:

  • Sepsis-induced acute kidney injury (AKI) is a critical complication with high mortality.
  • Mitochondrial dysfunction plays a key role in the pathogenesis of sepsis-induced AKI.
  • Targeting mitochondria offers a potential therapeutic strategy for AKI.

Purpose of the Study:

  • To investigate the protective effects and underlying mechanisms of the mitochondria-targeted antioxidant peptide SS-31 on sepsis-induced AKI.
  • To evaluate the impact of SS-31 on renal function, mitochondrial integrity, and apoptosis in a mouse model of sepsis-induced AKI.

Main Methods:

  • A mouse model of sepsis-induced AKI was established using cecal ligation and puncture (CLP).
  • Mice were treated with SS-31 peptide or saline.
  • Renal function markers (serum creatinine, BUN), kidney histopathology, mitochondrial ultrastructure, and apoptosis were assessed.
  • Expression levels of AMPK, PGC-1α, and cleaved caspase-3 were determined via Western blotting.

Main Results:

  • Sepsis significantly increased serum creatinine and BUN levels, induced kidney damage, mitochondrial dysfunction, and apoptosis.
  • SS-31 treatment markedly reduced serum creatinine and BUN levels, alleviated kidney histopathological damage, preserved mitochondrial structure, and decreased apoptosis.
  • SS-31 administration modulated the expression of AMPK, PGC-1α, and cleaved caspase-3.

Conclusions:

  • SS-31 peptide demonstrates significant protective effects against sepsis-induced AKI.
  • The mechanism involves maintaining mitochondrial homeostasis and inhibiting cell apoptosis.
  • SS-31 represents a promising therapeutic candidate for managing sepsis-induced AKI.

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
75
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
141
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
122
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
140
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
65